Pharmaceuticals
Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with "Top 100 Innovation CEO" Award
PALO ALTO, Calif., Sept. 21, 2021 /PRNewswire/ -- Koji Tanabe, Founder and CEO
of I Peace, Inc. (https://www.ipeace.com
2021-09-22 02:00
2063
FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis
RALEIGH, N.C., Sept. 21, 2021 /PRNewswire/ -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents. LEXETTE, a super potent topical corticosteroid, is now approved for the treatment ...
2021-09-21 22:00
5216
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
The solution offers superior ease of formulation, potential application versatility, and more comprehensive immune support compared to probiotics and other immune health ingredients SANTA CLARA, Calif., Sept. 21, 2021 /PRNewswire/ -- Based on its recent analysis of the North American immune hea...
2021-09-21 20:00
1960
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021
MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was present...
2021-09-20 22:51
7769
CStone presents clinical data from the China registrational bridging study on ivosidenib in patients with relapsed/refractory acute myeloid leukemia (R/R AML) with a susceptible IDH1 mutation at the 2021 ESMO Congress
* The data showed that ivosidenib demonstrated clinical efficacy in the treatment of Chinese adults with R/R AML with a susceptible IDH1 mutation. And ivosidenib was well tolerated and had a manageable safety profile * In August 2021, the National Medical Products Administration (NMPA) of Chin...
2021-09-20 20:00
5481
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial
* Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder * Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data by end of 2022 ADELAIDE, Australia, Sept....
2021-09-20 18:00
4625
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO
SHANGHAI, Sept. 19, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been ...
2021-09-20 08:24
10729
CStone presents preliminary results from a phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with the anti-PD-1 mAb CS1003 in patients with advanced solid tumors at ESMO 2021
SUZHOU, China, Sept. 19, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative cancer immunotherapies and precision medicines, today announced the preliminary results from t...
2021-09-19 09:00
4882
2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar
SHANGHAI, Sept. 18, 2021 /PRNewswire/ -- The 24th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) will be held online and in-person from 25th to 29th September 2021. In this meeting, Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb ser...
2021-09-18 20:00
12630
Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-09-18 08:00
16063
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dis...
2021-09-18 08:00
8225
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355
BEIJING, Sept. 17, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies called Tiannuojiancheng Pharm...
2021-09-17 20:00
5994
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of Serplulimab Injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with carboplatin and albumin-bound ...
2021-09-17 20:00
4970
111, Inc. Announces Participation in the Cantor Virtual Global Healthcare Conference
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that Senior Vice President, Investor Relations and...
2021-09-17 19:00
4815
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone
VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that cancer vaccine manufacturing partner Bio Elpida inLyon, France, has reached major milestones in the development of the bioproduction proce...
2021-09-17 15:00
6502
CStone will present registrational clinical study data of Sugemalimab in patients with stage III non-small cell lung cancer in an oral presentation at ESMO Congress 2021
* Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients withstage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy * The data showed that suge...
2021-09-17 08:00
4541
Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal
SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to include a third asset, MydCombi™, for development and commerc...
2021-09-17 08:00
2111
Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Everest Medicines
2021-09-17 06:30
7011
PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
RAUBLING, Germany and LYON, France, Sept. 17, 2021 /PRNewswire/ -- PharmaZell, the German producer of highly resilient and specialty APIs, andFrance-based Novasep, a leading CDMO focused on complex small molecules and ADCs have entered into exclusive negotiations to create a leading European plat...
2021-09-17 03:59
3464
COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients
TAIPEI, Sept.16, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its oral investigational new drug Antroquinonol (HOCENA®) has made headway withCOVID-19 treatment development in more broaden clinical ...
2021-09-16 18:05
2776
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 313 media titles]
2026-08-27 10:25
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
[Picked up by 304 media titles]
2026-08-24 10:00
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 297 media titles]
2026-08-25 10:00OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
[Picked up by 291 media titles]
2026-08-24 15:42
Most Read
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
2026-08-24 10:00
13355
OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
2026-08-24 15:42
13112
Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
2026-08-25 07:00
11162
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
6676